This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 -9. (Canceled)

10. (Currently Amended) The method of claim ~~1~~ 38, wherein ~~the cell cycle checkpoint activator~~ β-lapachone or a derivative or analog thereof, and imatinib ~~and the oncogenic kinase modulator~~ are administered intravenously, orally or intraperitoneally.

11. (Currently Amended) The method of claim ~~1~~ 38, wherein ~~the cell cycle checkpoint activator~~ β-lapachone or a derivative or analog thereof, and imatinib ~~and the oncogenic kinase modulator~~ are administered orally.

12. (Currently Amended) The method of claim ~~1~~ 38, wherein imatinib ~~the oncogenic kinase modulator~~ is administered orally.

13. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~ is administered intravenously.

14. (Currently Amended) The method of claim ~~1~~ 38, wherein imatinib ~~the oncogenic kinase modulator~~ is administered simultaneously with, preceding administration of, or following administration of ~~the cell cycle checkpoint activator~~ β-lapachone or a derivative or analog thereof.

15. (Currently Amended) The method of claim 14, wherein imatinib ~~the oncogenic kinase modulator~~ is administered following administration of ~~the cell cycle checkpoint activator~~ β-lapachone or a derivative or analog thereof.

16. (Currently Amended) The method of claim 15, wherein imatinib ~~the oncogenic kinase modulator~~ is administered within 24 hours after ~~the cell cycle checkpoint activator~~ β-lapachone or a derivative or analog thereof is administered.

17. (Currently Amended) The method of claim ~~1~~ 38, wherein the therapeutically effective amount of β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~, is

contained in a first vial, and imatinib ~~the oncogenic kinase modulator~~ is contained in a second vial, the contents of the first and second vials being administered to the patient simultaneously or sequentially.

18 -21. (Canceled)

22. (Currently Amended) The method of claim ~~5~~ 38, wherein imatinib is administered at a dosage of approximately 400, 600 or 800 mg/day.

23. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~ is administered at a dosage from about 100 to 500,000 μg per kilogram body weight of recipient per day.

24. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~ is administered at a dosage from about 1000 to 250,000 μg per kilogram body weight of recipient per day.

25. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~ is administered at a dosage from about 10,000 to 150,000 μg per kilogram body weight of recipient per day.

26. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~ is administered at a dosage from about 2 $mg/m^2$ to 5000 $mg/m^2$ per day.

27. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator is administered~~ at a dosage from about 20 $mg/m^2$ to 500 $mg/m^2$ per day.

28. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~ is administered at a dosage from about 30 to 300 $mg/m^2$ per day.

29. (Currently Amended) The method of claim ~~1~~ 38, wherein β-lapachone or a derivative or analog thereof ~~the cell cycle checkpoint activator~~, further comprises a pharmaceutically acceptable carrier.

30. (Original) The method of claim 29, wherein the pharmaceutically acceptable carrier is a water solubilizing carrier molecule selected from the group consisting of Poloxamer, Povidone K17, Povidone K12, Tween 80, ethanol, Cremophor/ethanol, polyethylene glycol (PEG) 400, propylene glycol, Trappsol, alpha-cyclodextrin or analogs thereof, beta-cyclodextrin or analogs thereof, and gamma-cyclodextrin or analogs thereof.

31. (Currently Amended) The method of claim ~~1~~ 38, wherein the subject is human.

32 - 37. (Canceled)

38. (Original) A method of treating multiple myeloma or chronic myelogenous leukemia in a human, the method comprising administering to the subject a therapeutically effective amount of β-lapachone or a derivative or analog thereof, and imatinib, such that the multiple myeloma or chronic myelogenous leukemia is treated.

39. (Canceled)